Company Will Host Conference Call Today at 4:30 PM ET / 1:30 PM PT

  • COR1 Aims to Provide an "Off the Shelf" Supply of Allogeneic CEnCs for Patients Suffering from Corneal Endothelial Disease
  • Utilizes the Company’s AlloSCOPE™ 5D Manufacturing Process, Featuring Seamless, Bioreactor-based Expansion and Differentiation
  • Proprietary "Thaw and Inject (TAI)" Formulation Offers an Immediate-use Cryopreserved Product Profile to Facilitate Long-Term Storage
  • Current Purity, Scale and Thaw-and-Inject Formulation Support a Superior Product Profile to Cadaver-Sourced Cells

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, "off the shelf", cell therapies for serious medical conditions, today provided an update on COR1, the Company’s allogeneic corneal endothelial cell (CEnC) transplant program, in preclinical development for the treatment of corneal endothelial disease. With COR1, Lineage is deploying its ophthalmology and cell manufacturing expertise to achieve consistent, large-scale production of allogeneic CEnCs. COR1 is a pluripotent cell derived transplant designed to address the current deficiencies of donor-derived (cadaver) CEnCs, which are currently approved in Japan, including limited supply, donor variability and quality, extensive processing and handling, and brief shelf-life. The Company has successfully utilized its proprietary AlloSCOPE cell manufacturing platform (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent cell Engineering) to achieve seamless precursor bioreactor-based expansion and differentiation to support CEnC production which, together with a thaw-and-inject formulation, we believe will offer a superior product profile and which meet Lineage’s internal criteria for continued preclinical advancement. The Company will host a conference call today at 4:30 p.m. Eastern Time to discuss the updates related to the COR1 program.